NCT02498860 (APICAL) is a Phase 2 clinical trial of Pemebit in Adenocarcinoma, sponsored by Chonnam National University Hospital.

Who is sponsoring NCT02498860?

NCT02498860 is sponsored by Chonnam National University Hospital.

What drugs are being tested in NCT02498860?

Interventions in NCT02498860: Pemebit, Cisplatin.

What condition does NCT02498860 study?

NCT02498860 studies Adenocarcinoma, Lung Neoplasm.

Is NCT02498860 still recruiting?

NCT02498860 is currently completed. Last updated 6 August 2021.

Last reviewed 2021-08-06 · How we verify

NCT02498860: APICAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung

Completed Phase 2 Last updated 6 August 2021

What this trial tests

Phase 2 trial testing Pemebit in Adenocarcinoma in 106 participants. Completed in 31 July 2021.

Timeline

1 September 2015

Primary endpoint
6 February 2018

31 July 2021

Quick facts

Lead sponsor	Chonnam National University Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	106
Start date	1 September 2015
Primary completion	6 February 2018
Estimated completion	31 July 2021
Sites	7 locations across South Korea

Drugs / interventions tested

Pemebit — full drug profile →
Cisplatin (cisplatin) — full drug profile →

Conditions studied

Adenocarcinoma — all drugs for Adenocarcinoma →
Lung Neoplasm — all drugs for Lung Neoplasm →

Sponsor

Chonnam National University Hospital

Who can join

20 and older, any sex, with Adenocarcinoma or Lung Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Two-Year Disease Free Survival Rate of Stage IB\~IIIA adenocarcinoma after Adjuvant Chemotherapy with Pemetrexed and Cisplatin will be assessed. A total of 106 patients will be recruited for 12 months, and followed for two years, thus the duration of study will be 36 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial.
Park CK, Oh HJ, Yoo SS, Lee SY, et al · · 2022 · cited 3× · PMID 36090637 · DOI 10.21037/tlcr-22-183

Verify or expand the search:

Other recruiting trials for Adenocarcinoma

Currently open trials in the same condition.

NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting
NCT06649474 — Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels · NA · recruiting
NCT05581121 — PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer · Phase 3 · recruiting
NCT06128343 — Anatomical-Clinical Base of Adenocarcinoma Pancreatic · recruiting
NCT05922930 — Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management · Phase 1, PHASE2 · recruiting

Other Chonnam National University Hospital trials

Trials by the same sponsor.

NCT07390461 — Effectiveness of Artificial Intelligence Integrated Mixed Reality-based High-Alert Medications Management Simulation Pro · NA · not yet recruiting
NCT07482228 — Long-term Clinical Outcomes After Retinal Artery Occlusion · recruiting
NCT06954714 — Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions · NA · recruiting
NCT07002164 — Timing of Coronary Angiography in NSTEMI Complicated by Acute HF · NA · recruiting
NCT06227754 — OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02498860 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chonnam National University Hospital
Last refreshed: 6 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02498860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing